Translating Science into Practice

Sign up for our email notifications for the latest Fresenius Medical Care insights, and stay connected to the best ideas in healthcare.

SUBSCRIBE

A Welcome from Dr. Franklin Maddux

Welcome to the 2018 Annual Medical Report. This year’s report — Go Further, Faster: Translating Science Into Practice — is a collection of 16 whitepapers by 29 diverse clinical thought leaders across the company, highlighting our proactive efforts to improve the care delivery system and address challenges and opportunities across the renal care spectrum. The report and its authors reflect the depth of our expertise, the breadth of our scientific and clinical explorations, and the strength of our commitment to continual learning for the benefit of the patients who entrust us with their care.

VIEW THE FULL REPORT

Translating Science Into Practice: FMCNA is an Ecosystem that Drives Progress

Franklin W. Maddux, MD, FACP

In a visionary outline of the vertically integrated Fresenius Medical Care North America ecosystem, Dr. Frank Maddux, FMCNA Chief Medical Officer and EVP for Clinical and Scientific Affairs, explores translating science into practice as a competitive advantage, and the quest to see emerging science as it evolves, to focus that science for the benefit of patients, and to harness the power of data-driven insights to reimagine the future of kidney care.

Regenerative Medicine: Immediate Reality and Long-Term Promise

Murat Sor, MD
Warren S. Krackov, MD, MA, MS
Catherina Madormo, RN, BSN

The emerging field of regenerative medicine holds immediate and long-term promise for patients with end-stage renal disease (ESRD). In particular, bioengineered vessels have more immediate potential to address current shortcomings in vascular access, emerging as cost effective, reliable and safe alternatives to arteriovenous fistulas (AVFs), catheters and grafts.

Cardiovascular Benefits of More Frequent Dialysis

Dinesh Chatoth, MD
Allan Collins, MD, FACP

Shorter, more frequent dialysis treatments can help improve cardiovascular complications and quality of life for end-stage renal disease (ESRD) patients. Given the prevalence of cardiovascular disease in patients with chronic kidney disease (CKD), with mortality rates 20 times higher than the general population, this has profound implications for patient care.